These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 22757653)
21. Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients. Jardi R; Rodriguez-Frias F; Schaper M; Ruiz G; Elefsiniotis I; Esteban R; Buti M J Viral Hepat; 2007 Dec; 14(12):835-40. PubMed ID: 18070286 [TBL] [Abstract][Full Text] [Related]
22. Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy. Liu F; Chen L; Yu DM; Deng L; Chen R; Jiang Y; Chen L; Huang SY; Yu JL; Gong QM; Zhang XX Gut; 2011 Sep; 60(9):1269-77. PubMed ID: 21292683 [TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238 [TBL] [Abstract][Full Text] [Related]
24. [Clinical characteristics and effect of secondary individualized therapy in chronic hepatitis B patients infected with the rtA181 mutation hepatitis B virus]. Ji FZ; Wang L; Yang BH; Zhao JJ; Liu F; Xue Y; Li T Zhonghua Gan Zang Bing Za Zhi; 2012 Apr; 20(4):280-4. PubMed ID: 22964149 [TBL] [Abstract][Full Text] [Related]
25. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. Margeridon-Thermet S; Shulman NS; Ahmed A; Shahriar R; Liu T; Wang C; Holmes SP; Babrzadeh F; Gharizadeh B; Hanczaruk B; Simen BB; Egholm M; Shafer RW J Infect Dis; 2009 May; 199(9):1275-85. PubMed ID: 19301976 [TBL] [Abstract][Full Text] [Related]
26. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance? Suzuki Y; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Miyakawa Y; Kumada H J Gastroenterol Hepatol; 2009 Mar; 24(3):429-35. PubMed ID: 19226381 [TBL] [Abstract][Full Text] [Related]
27. Analysis of hepatitis B virus genotyping and drug resistance gene mutations based on massively parallel sequencing. Han Y; Zhang Y; Mei Y; Wang Y; Liu T; Guan Y; Tan D; Liang Y; Yang L; Yi X J Virol Methods; 2013 Nov; 193(2):341-7. PubMed ID: 23773806 [TBL] [Abstract][Full Text] [Related]
28. Simultaneous emergence of entecavir resistance mutations in a nucleoside-naive chronic hepatitis B patient. Lee HW; Kim HJ; Hong SP; Cha BK; Chang HY; Choi CH; Do JH; Kim JG; Chang SK Intervirology; 2012; 55(5):380-4. PubMed ID: 22538265 [TBL] [Abstract][Full Text] [Related]
29. Development of peptide nucleic acid mediated polymerase chain reaction clamping (PMPC)--direct sequencing method for detecting lamivudine-resistant hepatitis B virus (HBV) variants with high sensitivity and specificity. Ogata N; Ichida T; Aoyagi Y; Kitajima I Rinsho Byori; 2003 Apr; 51(4):313-9. PubMed ID: 12747252 [TBL] [Abstract][Full Text] [Related]
30. A comparative study of ultra-deep pyrosequencing and cloning to quantitatively analyze the viral quasispecies using hepatitis B virus infection as a model. Ramírez C; Gregori J; Buti M; Tabernero D; Camós S; Casillas R; Quer J; Esteban R; Homs M; Rodriguez-Frías F Antiviral Res; 2013 May; 98(2):273-83. PubMed ID: 23523552 [TBL] [Abstract][Full Text] [Related]
31. [Entecavir - options and obstacles of an effective treatment for chronic hepatitis B]. Cornberg M; Manns MP Dtsch Med Wochenschr; 2010 Jan; 135(1-2):32-7. PubMed ID: 20024882 [TBL] [Abstract][Full Text] [Related]
32. Long-term monitoring drug resistance by ultra-deep pyrosequencing in a chronic hepatitis B virus (HBV)-infected patient exposed to several unsuccessful therapy schemes. Sede M; Ojeda D; Cassino L; Westergaard G; Vazquez M; Benetti S; Fay F; Tanno H; Quarleri J Antiviral Res; 2012 May; 94(2):184-7. PubMed ID: 22453135 [TBL] [Abstract][Full Text] [Related]
33. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. Chan HL; Chui AK; Lau WY; Chan FK; Wong ML; Tse CH; Rao AR; Wong J; Sung JJ J Med Virol; 2002 Oct; 68(2):182-7. PubMed ID: 12210406 [TBL] [Abstract][Full Text] [Related]
34. Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy in human immunodeficiency virus coinfected patients: performance of CLIP sequencing and line probe assay. Roque-Afonso AM; Férey MP; Mackiewicz V; Fki L; Dussaix E Antivir Ther; 2003 Dec; 8(6):627-34. PubMed ID: 14760897 [TBL] [Abstract][Full Text] [Related]
35. [Clinical application of microarray technique to quantify the lamivudine-resistant gene mutant of hepatitis B virus]. Huang XT; Zeng AP; Lin F Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Jun; 21(2):185-7. PubMed ID: 17653332 [TBL] [Abstract][Full Text] [Related]
36. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Sheldon J; Camino N; Rodés B; Bartholomeusz A; Kuiper M; Tacke F; Núñez M; Mauss S; Lutz T; Klausen G; Locarnini S; Soriano V Antivir Ther; 2005; 10(6):727-34. PubMed ID: 16218172 [TBL] [Abstract][Full Text] [Related]
37. Direct detection of lamivudine-resistant hepatitis B virus mutants by a multiplex PCR using dual-priming oligonucleotide primers. Kim JK; Lee HJ; Lee YJ; Chun JY; Lee IK; Lim YS; Suh DJ; Ko SY; Kim MH; Oh HB J Virol Methods; 2008 Apr; 149(1):76-84. PubMed ID: 18291537 [TBL] [Abstract][Full Text] [Related]
38. Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis. Chan HL; Chui AK; Lau WY; Chan FK; Hui AY; Rao AR; Wong J; Lai EC; Sung JJ Clin Transplant; 2004 Jun; 18(3):295-300. PubMed ID: 15142051 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization. Kim HS; Han KH; Ahn SH; Kim EO; Chang HY; Moon MS; Chung HJ; Yoo W; Kim SO; Hong SP Antivir Ther; 2005; 10(3):441-9. PubMed ID: 15918335 [TBL] [Abstract][Full Text] [Related]
40. [Construction and application of a genechip method for detection of hepatitis B virus lamivudine-resistant mutants and basal core promotor/Pre-C mutants]. Li B; Zhou BP; Peng JF; Chen LY; Zhang W; Tang W; Wang ZQ; Yin ZH; Xu LM; Luo RL; Li XH; Liu SY Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Aug; 23(4):309-12. PubMed ID: 20108783 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]